AcelRx Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACRX)

$2.50
-0.02 (-0.79 %)
(As of 09/22/2019 06:03 AM ET)
Today's Range
$2.50
Now: $2.50
$2.61
50-Day Range
$2.11
MA: $2.35
$2.71
52-Week Range
$1.99
Now: $2.50
$5.05
Volume774,399 shs
Average Volume749,682 shs
Market Capitalization$198.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.19
AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.15 million
Book Value$0.05 per share

Profitability

Net Income$-47,150,000.00
Net Margins-2,327.05%

Miscellaneous

Employees61
Market Cap$198.60 million
Next Earnings Date11/1/2019 (Estimated)
OptionableOptionable

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.


AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) released its earnings results on Monday, August, 5th. The specialty pharmaceutical company reported ($0.16) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.07. The specialty pharmaceutical company had revenue of $0.94 million for the quarter, compared to the consensus estimate of $1.55 million. View AcelRx Pharmaceuticals' Earnings History.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AcelRx Pharmaceuticals.

What price target have analysts set for ACRX?

8 equities research analysts have issued 1 year target prices for AcelRx Pharmaceuticals' shares. Their predictions range from $6.50 to $10.00. On average, they expect AcelRx Pharmaceuticals' stock price to reach $8.0714 in the next twelve months. This suggests a possible upside of 222.9% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.

What is the consensus analysts' recommendation for AcelRx Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.

What are Wall Street analysts saying about AcelRx Pharmaceuticals stock?

Here are some recent quotes from research analysts about AcelRx Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician's office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. " (7/9/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We are not at all dismayed by the relatively small revenues since there is no stocking for this direct shipment product and hospital formularies barely had an opportunity to meet during these five weeks. Management did note that among the five hospital formularies that did meet, all five have approved Dsuvia. Presently, the company knows of 41 more meetings by midyear. If approved, it will still take weeks to months for AcelRx’s Dsuvia reps to find time with these busy hospital/ASC healthcare practitioners (HCPs), REMS training to be completed (relatively brief however) and the product to be stocked. As many investors know, hospital launches are notoriously slow. However, the early signals are ahead of our expectations." (5/9/2019)

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

Media headlines about ACRX stock have been trending somewhat negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AcelRx Pharmaceuticals earned a news impact score of -1.3 on InfoTrie's scale. They also gave news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for AcelRx Pharmaceuticals.

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Amicus Therapeutics (FOLD), Novavax (NVAX), Amarin (AMRN), TG Therapeutics (TGTX), Cyberark Software (CYBR), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Fitbit (FIT) and Flexion Therapeutics (FLXN).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the folowing people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 51)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.61%), Vanguard Group Inc. (4.25%), D. E. Shaw & Co. Inc. (1.08%), Northern Trust Corp (0.37%), Wells Fargo & Company MN (0.32%) and Bank of New York Mellon Corp (0.32%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.

Which institutional investors are selling AcelRx Pharmaceuticals stock?

ACRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. Company insiders that have sold AcelRx Pharmaceuticals company stock in the last year include Badri N Dasu and Lawrence G Hamel. View Insider Buying and Selling for AcelRx Pharmaceuticals.

Which institutional investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., D. E. Shaw & Co. Inc., Vanguard Group Inc., Bank of New York Mellon Corp, Charles Schwab Investment Management Inc., Northern Trust Corp, A.R.T. Advisors LLC and Walleye Trading LLC. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $2.50.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $198.60 million and generates $2.15 million in revenue each year. The specialty pharmaceutical company earns $-47,150,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.View Additional Information About AcelRx Pharmaceuticals.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is http://www.acelrx.com/.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]


MarketBeat Community Rating for AcelRx Pharmaceuticals (NASDAQ ACRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  408 (Vote Outperform)
Underperform Votes:  331 (Vote Underperform)
Total Votes:  739
MarketBeat's community ratings are surveys of what our community members think about AcelRx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel